These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8588239)

  • 1. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation.
    Kahan BD; Murgia MG; Slaton J; Napoli K
    Ther Drug Monit; 1995 Dec; 17(6):672-5. PubMed ID: 8588239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus, a new, potent immunosuppressive agent.
    Kelly PA; Gruber SA; Behbod F; Kahan BD
    Pharmacotherapy; 1997; 17(6):1148-56. PubMed ID: 9399599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus in transplantation.
    Stepkowski SM; Tian L; Wang ME; Qu X; Napoli K; Kahan BD
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):383-90. PubMed ID: 9437494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry detection of intracytoplasmic cytokines after Neoral or sirolimus intake is an informative tool for monitoring in vivo immunosuppressive efficacy in renal transplant recipients.
    Tkaczuk J; Rostaing L; Puyoo O; Peres C; Abbal M; Durand D; Ohayon E
    Transplant Proc; 1998 Aug; 30(5):2400-1. PubMed ID: 9723518
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report--sirolimus rescue therapy for refractory renal allograft rejection.
    Slaton JW; Kahan BD
    Transplantation; 1996 Mar; 61(6):977-9. PubMed ID: 8623172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD
    J Nephrol; 2004; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients.
    Kahan BD
    Transplant Proc; 1998 Aug; 30(5):2185-8. PubMed ID: 9723435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation.
    Aspeslet LJ; Yatscoff RW
    Clin Ther; 2000; 22 Suppl B():B86-92. PubMed ID: 10823376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic monitoring of immunosuppressive drugs.
    Yatscoff RW; Aspeslet LJ; Gallant HL
    Clin Chem; 1998 Feb; 44(2):428-32. PubMed ID: 9474055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of therapeutic drug monitoring of rapamycin.
    Kahan BD; Napoli KL
    Transplant Proc; 1998 Aug; 30(5):2189-91. PubMed ID: 9723436
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.
    Stepkowski SM; Tian L; Napoli KL; Ghobrial R; Wang ME; Chou TC; Kahan BD
    Clin Exp Immunol; 1997 Apr; 108(1):63-8. PubMed ID: 9097913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of functional renal allograft tolerance with single-dose rapamycin based induction immunosuppression.
    Goggins WC; Fisher RA; Dattilo JB; Cohen DS; Tawes JW; Dattilo MP; Babcock GF; Frede SE; Wakely PE; Posner MP
    Transplantation; 1997 Jan; 63(2):310-4. PubMed ID: 9020336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus: a ten-year perspective.
    Kahan BD
    Transplant Proc; 2004; 36(1):71-5. PubMed ID: 15013304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.